Latest news with #Cassava
The Sun
05-05-2025
- Business
- The Sun
Zindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovation
DUBAI, UAE – Media OutReach Newswire - 5 May 2025 - Zindi, the leading professional network for data scientists and AI developers in emerging markets, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with Cassava Technologies, a global technology leader of African heritage, to deliver artificial intelligence (AI) solutions and GPU-as-a-Service (GPUaas) across the African continent. This partnership represents a significant step in accelerating digital transformation in Africa and will see the two organisations collaborate on several initiatives. These include using Cassava's GPUaaS capabilities for Zindi's AI solution development and identifying opportunities for both organisations to leverage one another's platforms and ecosystems. As Africa's pioneering data science competition platform, Zindi collaborates with companies, non-profit organisations, and government institutions to develop, curate, and prepare data-driven challenges. This partnership underscores their mutual commitment to nurturing AI talent and innovation throughout the continent. Zindi CEO and Co-Founder, Celina Lee states: 'Zindi is thrilled at the opportunity to partner with Cassava Technologies to strengthen African datasets and address local problems with locally developed solutions. Using Cassava's GPU capabilities, which are essential for handling the large and complex computations that AI and machine learning models require, and collaborating on the launch of a competition specifically aimed at nurturing Africa's AI talent will not only expose entrepreneurs and innovative solutions; it will help build new skills and create employment opportunities,' With the signing of this MOU, Cassava and Zindi are set to make significant inroads in Africa's AI landscape. The partnership supports Cassava's objective of providing world-class digital solutions and advancing responsible AI adoption, innovation, and growth in Africa. This follows its recent announcement of its plans to build Africa's first AI factory and the 2024 launch of Cassava's AI business. The issuer is solely responsible for the content of this announcement.
Malay Mail
05-05-2025
- Business
- Malay Mail
Zindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovation
DUBAI, UAE – Media OutReach Newswire - 5 May 2025 -, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with Cassava Technologies, a global technology leader of African heritage, to deliver artificial intelligence (AI) solutions and GPU-as-a-Service (GPUaas) across the African partnership represents a significant step in accelerating digital transformation in Africa and will see the two organisations collaborate on several initiatives. These include using Cassava's GPUaaS capabilities for Zindi's AI solution development and identifying opportunities for both organisations to leverage one another's platforms and Africa's pioneering data science competition platform, Zindi collaborates with companies, non-profit organisations, and government institutions to develop, curate, and prepare data-driven challenges. This partnership underscores their mutual commitment to nurturing AI talent and innovation throughout the the signing of this MOU, Cassava and Zindi are set to make significant inroads in Africa's AI landscape. The partnership supports Cassava's objective of providing world-class digital solutions and advancing responsible AI adoption, innovation, and growth in Africa. This follows its recent announcement of its plans to build Africa's first AI factory and the 2024 launch of Cassava's AI #Zindi The issuer is solely responsible for the content of this announcement. About Zindi Zindi is also present in the Caribbean. Join Saturday May 10th 2025 Barbados hackathon Zindi is the first uniquely African data science competition platform. Zindi hosts an entire data science ecosystem of scientists, engineers, academics, companies, NGOs, governments and institutions focused on solving Africa's most pressing problems. Zindi works with companies, non-profit organizations, and government institutions to develop, curate, and prepare data-driven challenges. Solutions are ranked automatically by the accuracy achieved. Whether you are testing the data science waters for the first time or trying to crack a persistent business problem with data, Zindi helps organizations push their creative boundaries at an affordable cost. For data scientists, from newbies to rock stars, Zindi is a place to access African datasets and solve African problems. Data scientists will find all the tools they need on Zindi to compete, share ideas, hone their skills, build their professional profiles, find career opportunities, and have fun!
Zawya
05-05-2025
- Business
- Zawya
Zindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovation
DUBAI, UAE – Media OutReach Newswire - 5 May 2025 - Zindi, the leading professional network for data scientists and AI developers in emerging markets, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with Cassava Technologies, a global technology leader of African heritage, to deliver artificial intelligence (AI) solutions and GPU-as-a-Service (GPUaas) across the African continent. This partnership represents a significant step in accelerating digital transformation in Africa and will see the two organisations collaborate on several initiatives. These include using Cassava's GPUaaS capabilities for Zindi's AI solution development and identifying opportunities for both organisations to leverage one another's platforms and ecosystems. As Africa's pioneering data science competition platform, Zindi collaborates with companies, non-profit organisations, and government institutions to develop, curate, and prepare data-driven challenges. This partnership underscores their mutual commitment to nurturing AI talent and innovation throughout the continent. Zindi CEO and Co-Founder, Celina Lee states: "Zindi is thrilled at the opportunity to partner with Cassava Technologies to strengthen African datasets and address local problems with locally developed solutions. Using Cassava's GPU capabilities, which are essential for handling the large and complex computations that AI and machine learning models require, and collaborating on the launch of a competition specifically aimed at nurturing Africa's AI talent will not only expose entrepreneurs and innovative solutions; it will help build new skills and create employment opportunities," With the signing of this MOU, Cassava and Zindi are set to make significant inroads in Africa's AI landscape. The partnership supports Cassava's objective of providing world-class digital solutions and advancing responsible AI adoption, innovation, and growth in Africa. This follows its recent announcement of its plans to build Africa's first AI factory and the 2024 launch of Cassava's AI business. Hashtag: #Zindi The issuer is solely responsible for the content of this announcement. About Zindi Zindi is also present in the Caribbean. Join Saturday May 10th 2025 Barbados hackathon Zindi is the first uniquely African data science competition platform. Zindi hosts an entire data science ecosystem of scientists, engineers, academics, companies, NGOs, governments and institutions focused on solving Africa's most pressing problems. Zindi works with companies, non-profit organizations, and government institutions to develop, curate, and prepare data-driven challenges. Solutions are ranked automatically by the accuracy achieved. Whether you are testing the data science waters for the first time or trying to crack a persistent business problem with data, Zindi helps organizations push their creative boundaries at an affordable cost. For data scientists, from newbies to rock stars, Zindi is a place to access African datasets and solve African problems. Data scientists will find all the tools they need on Zindi to compete, share ideas, hone their skills, build their professional profiles, find career opportunities, and have fun! Zindi
Globe and Mail
01-05-2025
- Business
- Globe and Mail
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, 'Cassava', the 'Company'), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bordey will be primarily responsible for leading Cassava's research and development efforts. Her scientific expertise will guide the Company's preclinical program to evaluate simufilam as a potential treatment for TSC-related epilepsy, and potentially for additional pipeline indications. Dr. Bordey currently serves as the Vice Chair of the Department of Neurosurgery at Yale School of Medicine, where she holds the Rothberg Endowed Chair. She will limit the time devoted to those duties to allow her to perform her new role with Cassava. 'We are thrilled to have Dr. Angélique Bordey join us. Dr. Bordey will be a tremendous boost to Cassava's efforts to transform the treatment paradigm for TSC-related epilepsy. Her research, published in Neuron and Science Translational Medicine, was the cornerstone of the recently granted patent that includes the use of simufilam to treat TSC-related epilepsy. Cassava's subsequent license agreement with Yale University for that patent opens the door to explore this potential indication for simufilam. We believe that Dr. Bordey's unique neuroscience expertise can be instrumental to advancing our preclinical program and that her stature as a leader in the TSC community may allow for productive study collaborations,' said Rick Barry, President and Chief Executive Officer of Cassava. 'Through my academic research and collaboration with the TSC Alliance, I have learned that TSC-related epilepsy is among the more challenging epilepsy syndromes to manage, often requiring innovative and individualized treatment approaches. It is exciting to work directly with the Cassava team to advance the evaluation of simufilam as a potential novel treatment for this devasting rare disease. I am hopeful that simufilam's unique mechanism of action will provide a new approach to treating TSC-related epilepsy,' said Dr. Angélique Bordey, SVP, Neuroscience of Cassava. About Angélique Bordey, PhD Dr. Bordey is a highly respected, widely published neuroscientist and tenured professor who has dedicated her career to understanding neuronal signaling and unlocking the neurobiology of diseases such as tuberous sclerosis complex. She has been a member of the Departments of Neurosurgery and Cellular and Molecular Physiology at Yale School of Medicine for more than two decades. In her role as Vice Chair, Department of Neurosurgery at Yale School of Medicine, Dr. Bordey holds the Rothberg Endowed Chair. Over the course of Dr. Bordey's academic career, her work has resulted in more than 125 publications, significant grant support and numerous invited lectures. Dr. Bordey has mentored and supervised numerous students and postdoctoral associates, overseen numerous grants and provided consulting advice to several biopharmaceutical companies. Dr. Bordey earned her PhD in Neuroscience at University Louis Pasteur, Strasbourg, France and completed her post-doctoral fellowship at the University of Alabama at Birmingham. Prior to that, she earned Master's Degrees from the University Louis Pasteur in Neurophysiology and the Ecole Polytechnique de Lyon in Chemistry. Dr. Bordey completed her Bachelor's Degree in Mathematics, Physics, and Chemistry at Blaise Pascal College and her Baccalaureate at Lycée Saint Joseph, Montlucon, France. About Cassava Sciences, Inc. Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially for additional pipeline indications. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. The Company is based in Austin, Texas. For more information, please visit: For More Information Contact: Investors Sandya von der Weid svonderweid@ Company Eric Schoen, Chief Financial Officer (512) 501-2450 ESchoen@ IR@ Cautionary Note Regarding Forward-Looking Statements: This news release contains forward-looking statements that include but are not limited to statements regarding: our plans to conduct preclinical studies of simufilam relating to seizures in TSC, the potential for simufilam as a treatment for TSC-related epilepsy and other indications, the timing of anticipated milestones, and management appointments and comments made by our employees. These statements may be identified by words such as 'anticipate', 'before,' 'believe', 'could', 'expect', 'forecast', 'intend', 'may', 'pending,' 'plan', 'possible', 'potential', 'prepares for,' 'will', and other words and terms of similar meaning. Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to efficiently discontinue the Company's Alzheimer's disease development program, the ability to advance preclinical studies related to TSC-related epilepsy, and other risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at All of our pharmaceutical assets under development are investigational product candidates. They have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world. Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish. We are in the business of new drug discovery, development and commercialization. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery, development and commercialization, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
Associated Press
01-05-2025
- Business
- Associated Press
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, 'Cassava', the 'Company'), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bordey will be primarily responsible for leading Cassava's research and development efforts. Her scientific expertise will guide the Company's preclinical program to evaluate simufilam as a potential treatment for TSC-related epilepsy, and potentially for additional pipeline indications. Dr. Bordey currently serves as the Vice Chair of the Department of Neurosurgery at Yale School of Medicine, where she holds the Rothberg Endowed Chair. She will limit the time devoted to those duties to allow her to perform her new role with Cassava. 'We are thrilled to have Dr. Angélique Bordey join us. Dr. Bordey will be a tremendous boost to Cassava's efforts to transform the treatment paradigm for TSC-related epilepsy. Her research, published in Neuron and Science Translational Medicine, was the cornerstone of the recently granted patent that includes the use of simufilam to treat TSC-related epilepsy. Cassava's subsequent license agreement with Yale University for that patent opens the door to explore this potential indication for simufilam. We believe that Dr. Bordey's unique neuroscience expertise can be instrumental to advancing our preclinical program and that her stature as a leader in the TSC community may allow for productive study collaborations,' said Rick Barry, President and Chief Executive Officer of Cassava. 'Through my academic research and collaboration with the TSC Alliance, I have learned that TSC-related epilepsy is among the more challenging epilepsy syndromes to manage, often requiring innovative and individualized treatment approaches. It is exciting to work directly with the Cassava team to advance the evaluation of simufilam as a potential novel treatment for this devasting rare disease. I am hopeful that simufilam's unique mechanism of action will provide a new approach to treating TSC-related epilepsy,' said Dr. Angélique Bordey, SVP, Neuroscience of Cassava. About Angélique Bordey, PhD Dr. Bordey is a highly respected, widely published neuroscientist and tenured professor who has dedicated her career to understanding neuronal signaling and unlocking the neurobiology of diseases such as tuberous sclerosis complex. She has been a member of the Departments of Neurosurgery and Cellular and Molecular Physiology at Yale School of Medicine for more than two decades. In her role as Vice Chair, Department of Neurosurgery at Yale School of Medicine, Dr. Bordey holds the Rothberg Endowed Chair. Over the course of Dr. Bordey's academic career, her work has resulted in more than 125 publications, significant grant support and numerous invited lectures. Dr. Bordey has mentored and supervised numerous students and postdoctoral associates, overseen numerous grants and provided consulting advice to several biopharmaceutical companies. Dr. Bordey earned her PhD in Neuroscience at University Louis Pasteur, Strasbourg, France and completed her post-doctoral fellowship at the University of Alabama at Birmingham. Prior to that, she earned Master's Degrees from the University Louis Pasteur in Neurophysiology and the Ecole Polytechnique de Lyon in Chemistry. Dr. Bordey completed her Bachelor's Degree in Mathematics, Physics, and Chemistry at Blaise Pascal College and her Baccalaureate at Lycée Saint Joseph, Montlucon, France. About Cassava Sciences, Inc. Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially for additional pipeline indications. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. The Company is based in Austin, Texas. For more information, please visit: For More Information Contact: Investors Sandya von der Weid [email protected] Company Eric Schoen, Chief Financial Officer (512) 501-2450 [email protected] [email protected] Cautionary Note Regarding Forward-Looking Statements: This news release contains forward-looking statements that include but are not limited to statements regarding: our plans to conduct preclinical studies of simufilam relating to seizures in TSC, the potential for simufilam as a treatment for TSC-related epilepsy and other indications, the timing of anticipated milestones, and management appointments and comments made by our employees. These statements may be identified by words such as 'anticipate', 'before,' 'believe', 'could', 'expect', 'forecast', 'intend', 'may', 'pending,' 'plan', 'possible', 'potential', 'prepares for,' 'will', and other words and terms of similar meaning. Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to efficiently discontinue the Company's Alzheimer's disease development program, the ability to advance preclinical studies related to TSC-related epilepsy, and other risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at All of our pharmaceutical assets under development are investigational product candidates. They have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world. Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
